Windlas Biotech Limited (NSE:WINDLAS) filed an exchange notice on 5 August 2026 informing BSE and NSE that it will host a conference call on Tuesday, 11 August 2026 at 11:30 AM IST to discuss its financial performance for the quarter ended 30 June 2026.
Key Highlights
- The earnings call for Q1FY27 is scheduled for Tuesday, 11 August 2026, at 11:30 AM IST, as disclosed in the filing dated 5 August 2026.
- Managing Director Mr. Hitesh Windlass and CEO and CFO Ms. Komal Gupta will represent management on the call.
- International dial-in access has been provided for participants in Hong Kong, Singapore, the UK, and the USA via toll-free numbers.
- The filing was submitted pursuant to Clause 15 of Schedule III, Part A, Para A, read with Regulation 30 of the SEBI LODR Regulations, 2015.
About the Company
Windlas Biotech Limited (NSE:WINDLAS) is a Dehradun, Uttarakhand-based pharmaceutical contract development and manufacturing organisation. The company provides formulation development, contract manufacturing, and branded generic products, operating manufacturing facilities in the Dehradun region and serving domestic and international pharmaceutical clients across multiple dosage forms including oral solids and liquids.
Announcement in Detail
Windlas Biotech Limited filed a notice with BSE and NSE on 5 August 2026, disclosing that a conference call to discuss its financial results for the quarter ended 30 June 2026 (Q1FY27) would be held on Tuesday, 11 August 2026 at 11:30 AM IST. The filing was made in compliance with Clause 15 of Schedule III, Part A, Para A, read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The call will feature Managing Director Mr. Hitesh Windlass and CEO and CFO Ms. Komal Gupta as management representatives. Dial-in numbers have been provided for domestic participants as well as toll-free lines covering Hong Kong, Singapore, the UK, and the USA. Further information is available through investor relations contacts Ankit Jain and Manveer Sharma at Stellar IR.
Impact on Investors
Investors will note that the scheduled earnings call provides a formal, structured opportunity to assess Windlas Biotech's financial performance for the quarter ended 30 June 2026. The filing shows that both the Managing Director and the CEO and CFO will participate, indicating a senior-level engagement with the investment community. Shareholders will observe that international dial-in access broadens participation beyond domestic investors, reflecting the company's outreach to a wider institutional audience. The disclosed terms indicate this is a procedural announcement; no financial figures for Q1FY27 have been released in this filing.
Sector / Market Context
India's pharmaceutical contract manufacturing sector has seen sustained activity, with domestic CDMO players benefiting from increased outsourcing by both domestic branded generic companies and global innovators seeking cost-efficient manufacturing partners. According to industry body data, India's pharmaceutical exports have consistently ranked among the country's top foreign exchange earners, providing a stable demand backdrop for formulation-focused contract manufacturers such as Windlas Biotech.